Publications by authors named "Peter J Eddowes"
Article Synopsis
- Scientists studied a health problem called MASH, which affects people's livers, and worked on two tests to help doctors tell if someone has it.
- They looked at data from over 3,000 people to make sure their first test, called acMASH, worked well, and then created a new test called acFibroMASH to find more severe cases.
- The new acFibroMASH test was better at predicting who might have future liver problems compared to another test, showing it's a useful tool for doctors to keep patients healthy.
Noninvasive monitoring of disease activity in autoimmune hepatitis (AIH) has potential advantages for patients for whom liver biopsy is invasive and with risk. We sought to understand the association of multiparametric magnetic resonance imaging (mpMRI) with clinical course of patients with AIH. We prospectively recruited 62 patients (median age, 55 years; 82% women) with clinically confirmed AIH.
View Article and Find Full Text PDFArticle Synopsis
- Liver biopsy is often needed to assess fibrosis in non-alcoholic fatty liver disease (NAFLD) patients, but the study explores alternatives to potentially reduce this necessity.
- The study compares three diagnostic methods: liver stiffness measurement by vibration controlled transient elastography (LSM-VCTE), the Fibrosis-4 Index (FIB-4), and the NAFLD Fibrosis Score (NFS) using data from 5735 patients.
- The findings suggest that combining these diagnostic tests can effectively differentiate between advanced fibrosis and cirrhosis, reducing the number of biopsies required in these patients.
Article Synopsis
- More people are getting liver transplants and living well afterward, so doctors are paying more attention to how they follow up with patients in different locations.
- The study looked at liver transplant patients from 1987 to 2016 in two places: Nottingham, UK, and Ottawa, Canada, to see how they were doing over the years.
- The results showed that patients in both places lived long and healthy lives after their transplants, and the new healthcare setup helps them get care closer to home without any problems.
Article Synopsis
- The study evaluates the effectiveness of the Controlled Attenuation Parameter (CAP) as a non-invasive tool for assessing liver steatosis in obese patients, with a focus on establishing diagnostic cutoffs and performance accuracy.
- An individual patient data meta-analysis included data from 16 studies, encompassing 2,346 patients with various liver diseases and varying body mass indices (BMIs).
- Results showed that the majority of patients had non-alcoholic fatty liver disease (NAFLD), and the XL probe was recommended for assessing them, highlighting the need for standardized diagnostic criteria.
Background: The burden of non-alcoholic fatty liver disease (NAFLD) is increasing globally, and a major priority is to identify patients with non-alcoholic steatohepatitis (NASH) who are at greater risk of progression to cirrhosis, and who will be candidates for clinical trials and emerging new pharmacotherapies. We aimed to develop a score to identify patients with NASH, elevated NAFLD activity score (NAS≥4), and advanced fibrosis (stage 2 or higher [F≥2]).
Methods: This prospective study included a derivation cohort before validation in multiple international cohorts.
Background & Aims: We estimated the accuracy of FibroScan vibration-controlled transient elastography controlled attenuation parameter (CAP) and liver stiffness measurement (LSMs) in assessing steatosis and fibrosis in patients with suspected nonalcoholic liver disease (NAFLD).
Methods: We collected data from 450 consecutive adults who underwent liver biopsy analysis for suspected NAFLD at 7 centers in the United Kingdom from March 2014 through January 2017. FibroScan examinations with M or XL probe were completed within the 2 weeks of the biopsy analysis (404 had a valid examination).
LiverMultiScan is an emerging diagnostic tool using multiparametric MRI to quantify liver disease. In a two-centre prospective validation study, 161 consecutive adult patients who had clinically-indicated liver biopsies underwent contemporaneous non-contrast multiparametric MRI at 3.0 tesla (proton density fat fraction (PDFF), T1 and T2* mapping), transient elastography (TE) and Enhanced Liver Fibrosis (ELF) test.
View Article and Find Full Text PDFObjective: Primary sclerosing cholangitis (PSC) is the classical hepatobiliary manifestation of IBD. This clinical association is linked pathologically to the recruitment of mucosal T cells to the liver, via vascular adhesion protein (VAP)-1-dependent enzyme activity. Our aim was to examine the expression, function and enzymatic activation of the ectoenzyme VAP-1 in patients with PSC.
View Article and Find Full Text PDF